The guidelines, titled BRIDGE, are set to be released in 2025.
As more and more pharmaceutical companies are looking to incorporate AI into their processes, it’s becoming clear that there isn’t just one single way to use to technology. Due to its versatility, there are examples of it being added to processes across the entire industry, from everything to marketing, drug development, and even candidate selection.
However, this also makes incorporating the technology much more complicated. Aidoc, a clinical AI company, announced that it has partnered with NVIDIA to develop a blueprint for resilient integration and deployment of guided excellence, otherwise known as BRIDGE.1 The guidelines are set to be unveiled in 2025.
In a press release, Aidoc chief transformation officer Demetri Giannikopoulos said, “AI holds the potential to revolutionize patient care, but its progress has been stalled by fragmented systems and the inability to scale effectively. The BRIDGE guideline will focus on breaking down these barriers, offering a powerful, evidence-based framework that health systems can rely on not just adopt AI but to help scale it across their operations. This will drive both operational efficiency and significantly better outcomes for patients and clinicians alike."
In September, Aidoc launched seven new AI solutions to be used by healthcare companies operating in Europe.2 Four of the algorithms were designed to provide solutions triaging urgent pathologies while the other three provide new quantification solutions for cardiovascular and neurological conditions.
In a press release, Aidoc’s vice president of Europe Alexander Boehmcker said, “Health systems in Europe face severe challenges with increasing patient backlogs and staff shortages. To address these challenges, we are now taking clinical AI to the next level by increasing the speed and the scope of developing and implementing new AI-modules. Aidoc has already established itself as the leading clinical AI platform. With the introduction of these new solutions, we have scaled up our capability to flag more pathologies, and provide important measurements with our new quantification solutions. Coupled with our platform's ability to rapidly activate care teams and ensure robust patient follow-up, we're poised to deliver better outcomes for patients and providers. I am especially proud that now all our Aidoc AI-modules are CE-marked under the new MDR.”
In June of this year, Aidoc announced new patient-centric AI-powered technology designed to boost clinic volume and improve patient care.3
At the time, Aidoc CEO Elad Walach said, “Aidoc's AI technology is a transformative force in patient management. Our platform, with its diverse integrated solutions, doesn't just enhance diagnostic precision—it revolutionizes the entire follow-up process, ensuring no patient falls through the cracks. By integrating comprehensive data analysis with clinical insights, we empower healthcare providers to deliver timely and effective care, ultimately setting a new benchmark for patient outcomes and operational efficiency."
In the same press release, assistant professor of vascular surgery at the Yale School of surgery and Yale School of Medicine Edouard Aboian, MD, said, "Aidoc's comprehensive patient management platform has transformed our approach to patients with abdominal aortic aneurysms (AAA). The integration of AI technology into our workflow has increased the number of AAA patients, improved long-term follow-up and greatly reduced the time to appointment and intervention. This technology has truly bridged the gap between radiologic findings and patient care, allowing us to provide timely and effective treatments."
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.